These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531 [TBL] [Abstract][Full Text] [Related]
3. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521 [TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation. Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917 [TBL] [Abstract][Full Text] [Related]
5. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367 [TBL] [Abstract][Full Text] [Related]
6. Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease. Faiyaz-Ul-Haque M; Jamil M; Aslam M; Abalkhail H; Al-Dayel F; Basit S; Nawaz Z; Zaidi SHE Cancer Genet; 2020 May; 243():1-6. PubMed ID: 32179488 [TBL] [Abstract][Full Text] [Related]
7. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678 [TBL] [Abstract][Full Text] [Related]
8. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. Gläsker S; Bender BU; Apel TW; Natt E; van Velthoven V; Scheremet R; Zentner J; Neumann HP J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):758-62. PubMed ID: 10567493 [TBL] [Abstract][Full Text] [Related]
9. Role of VHL gene mutation in human cancer. Kim WY; Kaelin WG J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513 [TBL] [Abstract][Full Text] [Related]
10. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Woodward ER; Eng C; McMahon R; Voutilainen R; Affara NA; Ponder BA; Maher ER Hum Mol Genet; 1997 Jul; 6(7):1051-6. PubMed ID: 9215674 [TBL] [Abstract][Full Text] [Related]
11. von Hippel-Lindau disease: a clinical and scientific review. Maher ER; Neumann HP; Richard S Eur J Hum Genet; 2011 Jun; 19(6):617-23. PubMed ID: 21386872 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. Maher ER; Webster AR; Richards FM; Green JS; Crossey PA; Payne SJ; Moore AT J Med Genet; 1996 Apr; 33(4):328-32. PubMed ID: 8730290 [TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Decker HJ; Weidt EJ; Brieger J Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583 [TBL] [Abstract][Full Text] [Related]
14. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415 [TBL] [Abstract][Full Text] [Related]
15. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer]. Moch H Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708 [TBL] [Abstract][Full Text] [Related]
16. Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH. Decker HJ; Neuhaus C; Jauch A; Speicher M; Ried T; Bujard M; Brauch H; Störkel S; Stöckle M; Seliger B; Huber C Hum Genet; 1996 Jun; 97(6):770-6. PubMed ID: 8641695 [TBL] [Abstract][Full Text] [Related]
17. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Crossey PA; Foster K; Richards FM; Phipps ME; Latif F; Tory K; Jones MH; Bentley E; Kumar R; Lerman MI Hum Genet; 1994 Jan; 93(1):53-8. PubMed ID: 8270255 [TBL] [Abstract][Full Text] [Related]
19. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Martinez A; Fullwood P; Kondo K; Kishida T; Yao M; Maher ER; Latif F Mol Pathol; 2000 Jun; 53(3):137-44. PubMed ID: 10897333 [TBL] [Abstract][Full Text] [Related]
20. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease. Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]